Integrated Boost to the Dominant Intraprostatic Nodule Based on Ga-68 PSMA PET/MR Study of SBRT With Prostate Cancer

A Phase I Integrated Boost to the Dominant Intraprostatic Nodule Based on Ga-68 Prostate-Specific Membrane Antigen (PSMA) PET/MR Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer

Sponsors

Lead Sponsor: Changhai Hospital

Source Changhai Hospital
Brief Summary

The aim of this study is to test the safety and efficacy of integrated boost to the dominant intraprostatic nodule based on Ga-68 Prostate-Specific Membrane Antigen (PSMA) PET/MR in Stereotactic Body Radiation Therapy (SBRT) in localized prostate carcinoma in patients for whom the standard treatment is the irradiation of the entire prostate gland with or without seminal vesicles accompanied or not by hormonal therapy.

Detailed Description

Radiotherapy is considered standard of care treatment for prostate cancer. In light of the accumulating clinical evidence favoring the use of hypo fractionation, SBRT regimen might constitute a much more convenient non-invasive and highly efficient outpatient therapy. Although the proposed extreme hypofractionated radiotherapy approach was expected to provide excellent local control of the primary prostate cancer, a proportion of patients with intermediate- or high-risk disease may have recurrences with local recurrence or distant metastasis in the future, requiring strategies to minimize systemic disease. Ga-68 PSMA PET/MR has high accuracy in the diagnosis and staging of prostate cancer. In this protocol, pretreatment Ga-68 PSMA PET/MR and CT scanning were performed in all patients as well as the imaging fusion before delineating the target. This study would explore the simultaneously integrated boost or equential integrated boost to the dominant intraprostatic nodule based on Ga-68 PSMA PET/MR in SBRT.

Overall Status Recruiting
Start Date November 1, 2020
Completion Date May 1, 2023
Primary Completion Date May 1, 2022
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
The Probability of Acute genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction 90 days after the first fraction of radiotherapy treatment
Secondary Outcome
Measure Time Frame
The Probability of Chronic genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction (ED) > 90 days and up to 3 years from the start of protocol treatment
1-year Biochemical Progression-free Survival (bPFS) Assessment at 1-year
1-year Local Progression-Free-Survival(LPFS) Assessment at 1-year
1-year Distant Metastasis Free Survival(DMFS) Assessment at 1-year
1-year Overall Survival (OS) Assessment at 1-year
Enrollment 20
Condition
Intervention

Intervention Type: Radiation

Intervention Name: Stereotactic Body Radiation Therapy (SBRT)

Description: Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.

Arm Group Label: 1

Other Name: androgen deprivation therapy (ADT)

Eligibility

Criteria:

Inclusion Criteria: - Histologically confirmed adenocarcinoma of the prostate - tumor clinical stage cT1-3N0M0 according to AJCC TNM 2017 - Without any treatment of prostate cancer including radiotherapy, ADT, chemotherapy, focal treatment, etc. - With the examination of Ga-68 PSMA PET/MR - International Prostate Symptom Score(IPSS)<15 (alpha blockers allowed), without severe urethral obstruction symptoms - ECOG performance status 0-2 - Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures Exclusion Criteria: - Prior pelvic RT - A tumor located at less than 3 mm from the urethra or rectum when measured at the MRI - Tumor clinical stage cT4, with metastases including bone, lymph nodes or organ metastasis - Histologically confirmed neuroendocrine tumor or small cell carcinoma of the prostate - Severe or active co-morbidity likely to impact on the advisability of SBRT like severe liver or kidney dysfunction, etc. - Patients with other malignancies, or acute or other severe infections, with ulcerative colitis, inflammatory bowel disease, etc. - Patients who have participated in other clinical trials for less than three months - Patients have acute prostatitis or chronic prostatitis with urinary symptoms - Urine routine indicates obvious urinary system infection and no significant improvement after anti-infective treatment, or conversion to recurrent urinary system infection - Unsuitable to participate in this clinical trial judged by the investigator

Gender: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Healthy Volunteers: No

Overall Contact

Last Name: Huojun Zhang, PhD

Phone: 021-31162222

Email: [email protected]

Location
Facility: Status: Contact: Shanghai Changhai Hospital Huojun Zhang, PhD 021-31162222 [email protected]
Location Countries

China

Verification Date

October 2020

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Changhai Hospital

Investigator Full Name: Zhang Huo Jun

Investigator Title: Clinical Professor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: 1

Type: Experimental

Description: Simultaneously integrated boost or sequential integrated boost Simultaneously integrated boost Prostate tumor: starting dose 8.7 Gy per fraction in 5 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy. Sequential integrated boost Prostate tumor: starting dose 7.25 Gy per fraction in 6 fractions (total 43.5 Gy) Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions. Total 36.25 Gy.

Acronym SBRT
Patient Data No
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov